Is there still a role for abatacept in the treatment of lupus?

Expert Opinion on Biological Therapy

Volumn 14, Issue 9, 2014, Pages 1345-1350

  Hoi, Alberta ^a,b   Littlejohn, Geoff ^a,b  

^a SOUTHERN HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Abatacept; Biologics; Lupus; Lupus nephritis; Targeted therapy

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ANIMAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMAN; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PHYSIOLOGY; PROCEDURES; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; HUMANS; IMMUNOCONJUGATES; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84905826903     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.935329     Document Type: Review

References (25)

1. Uramoto KM, Michet CJ, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999;42(1):46-50
2. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265(5176):1225-7
3. Silverman GJ. Targeting of B cells in SLE: Rationale and therapeutic opportunities. Bull NYU Hosp Jt Dis 2006;64(1-2):51-6
4. Chu EB, Hobbs MV, Wilson CB, et al. Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. J Immunol 1996;156(3):1262-8
5. Daikh DI, Wofsy D. Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166(5):2913-16
6. Crispín JC, Tsokos GC. Novel molecular targets in the treatment of systemic lupus erythematosus. Autoimmun Rev 2008;7(3):256-61
7. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335(18):1369-1377
8. Tsokos GC, Liossis SN. Immune cell signaling defects in lupus: Activation, anergy and death. Immunol Today 1999;20(3):119-24
9. Mihara M, Tan I, Chuzhin Y, et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106(1):91-101
10. Liu Z, Davidson A. Taming lupus-A new understanding of pathogenesis is leading to clinical advances. Ann Pharmacother 2012;18(6):871-82
11. Kammer GM. Immunotherapy tackles lupus. Nat Med 2002;8(12):1356-8
12. Foell J, Mittler RS. Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus. Springer Semin Immunopathol 2006;28(2):153-62
13. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174(3):561-9
14. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-Threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62(10):3077-87
15. Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: Results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study [abstract]. Arthritis Rheum 2014;66(2):379-89
16. Hoi AY, Littlejohn GO. Abatacept in the treatment of lupus. Expert Opin Biol Ther 2012;12(10):1399-406
17. Merrill JT. Co-stimulatory molecules as targets for treatment of lupus. Clin Immunol 2013;148(3):369-75
18. Wofsy D, Askanase A, Cagnoli A. Treatment of lupus nephritis with abatacept plus low-dose pulse cyclophosphamide followed by azathioprine (the Euro-Lupus Regimen): Twenty-four week data from a doubleblind controlled trial [abstract]. Arthritis Rheum 2013;65(Suppl 10):884
19. Kremer JM, Russell AS, Emery P, et al. Long-Term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011;70(10):1826-30
20. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63(4):939-48
21. Furie R, Nicholls K, Cheng T-T, et al. Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study. Arthritis Rheum 2014;66(2):379-89
22. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012;64(11):3660-5
23. Gordon C. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42(11):1372-9
24. Yee C-S, Isenberg DA, Prabu A, et al. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis 2008;67(6):873-6
25. Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999;42(12):2682-8